We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

FTC Admin. Judge Says Endo-Impax Opana Deal Is Lawful

Law360 (May 18, 2018, 10:33 PM EDT) -- A patent deal in which Endo Pharmaceuticals Inc. paid generic-drug maker Impax Laboratories Inc. to forgo launching a generic version of an opioid pain medication did not violate consumer protection statutes, a Federal Trade Commission administrative law judge ruled Friday, because the settlement’s pro-competitive benefits outweighed its anti-competitive harms.

Administrative Law Judge D. Michael Chappell said the FTC’s complaint against the 2010 deal must be dismissed because the agreement granted Impax a broad patent license covering Endo’s Opana ER-related patents, enabling Impax to sell generic Opana...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.